Back to search results

Early Cancer Detection for Firefighters

This study is looking at new ways to find cancer early in firefighters. It's testing two different multi-cancer early detection (MCED) tests: Elypta's MCED test and Proteotype's MCED test. These tests use blood and urine samples to look for signs of cancer. The study wants to see how well these tests can find cancer (sensitivity) and how accurately they can tell if someone doesn't have cancer (specificity). They also want to know how often a positive test truly means cancer (positive predictive value) and how often a negative test truly means no cancer (negative predictive value). You can join if you are 18 or older, currently work as a firefighter, are part of Vincere's First Responder Cancer Screening Program, and can give blood and urine samples. The study plans to enroll 2000 participants.

Study design
This is an observational study, meaning researchers will watch and collect information from 2000 firefighters over time. It is not testing a new treatment, but rather how well certain tests work.
What's involved
You would need to donate blood and urine samples. The study will follow participants for up to 7 years for the Elypta test and up to 2030 for the Proteotype test.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 7 years for the Elypta test and up to 2030 for the Proteotype test.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05780957

Multi-Cancer Early Detection (MCED) of Firefighters

Recruiting
Not specifiedAges 18+Observational
Vincere Cancer Center
~2,000 participants
Updated 2025-11-05 on ClinicalTrials.gov
What's tested:MCED

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Sensitivity, specificity, positive and negative predictive performance values (PPV and NPV) to detect cancer using Elypta's MCED test, as measured in plasma, in urine, and in plasma and urine combined
Measured over Up to 7 years
+1 more outcome measured

Conditions

Cancer

Explore related trials

Malignant Neoplasm

Where it's being run

1 sites across 1 states
Arizona1

Study leadership

  • Vershalee Shukla, MD · PRINCIPAL_INVESTIGATOR · Vincere Cancer Center

Who to contact

Christine Lau, MD
[email protected]
480-306-5390
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18 years of age or older
Currently employed as a firefighter, full-time or part-time
Taking part in Vincere's First Responder Cancer Screening Program
Able to donate blood and urine sample
Able to provide informed consent to participate in the study

Exclusion

Deemed medically unfit for sample donation
Personal history of cancer in the last 5 years (with the exception of non-melanoma skin cancer)

What this trial measures

  • Sensitivity, specificity, positive and negative predictive performance values (PPV and NPV) to detect cancer using Elypta's MCED test, as measured in plasma, in urine, and in plasma and urine combinedUp to 7 years
  • Sensitivity, specificity, positive and negative predictive performance values to detect cancer using Proteotype's MCED test, as measured in plasma.Up to 2030